BMO Capital initiated coverage of LifeStance (LFST) with an Outperform rating and $8 price target With new initiatives in place to boost growth, attention has turned to their effectiveness, the analyst tells investors in a research note. LifeStance’s focus is shifting from solely adding clinicians to also enhancing their productivity, while expanding into specialty care offers additional upside, the firm says, adding that the stock appears attractively valued.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LFST:
- Positive Outlook for LifeStance Health Group: Overcoming Challenges and Driving Growth with Strategic Initiatives
- Strong Performance and Promising Outlook: Richard Close Reaffirms Buy Rating for Lifestance Health Group
- LifeStance price target raised to $10 from $9 at UBS
- LifeStance Health Group Reports Strong Q3 2025 Results
- LifeStance Health’s Earnings Call: Strong Growth Amid Challenges